There are over 2 billion people suffering with chronic disease such as hypertension, diabetes or heart disease. Reduction of the non-communicable disease (NCD) burden is a global development imperative. United Nations Sustainable Development Goal (SDG) 3 includes target 3·4 to reduce premature NCD mortality by a third by 2030. Progress on SDG target 3·4 will have a central role in determining the success of at least nine SDGs.
According to the World Health organisation, the key facts are :
The enormous burden of chronic disease, and the associated demand for new treatments and novel approaches to care, is driven by several factors including:
Despite the increase in healthcare expenditures, there remain significant market gaps that, if appropriately addressed, can significantly improve health and patient outcomes.
Investing in better management of NCDs is critical. Management of NCDs includes detecting, screening and treating these diseases, and providing access to palliative care for people in need. High-impact, essential NCD interventions can be delivered through a primary health care approach to strengthen early detection and timely treatment. Evidence shows such interventions are excellent economic investments because, if provided early to patients, they can reduce the need for more expensive treatment.
Many of these remain undiagnosed, are on inappropriate treatment, or unlikely to receive treatment whatsoever
Approximately 37% of these deaths occur before people reach the age of 70.
George Health, a “profit with purpose” business, is well positioned to help address these market gaps by delivering high-impact, disruptive, affordable, and widely-scalable products and technologies developed from the world-leading research of The George Institute.
George Health is committed to ensuring that its impact extends to many millions of vulnerable people and is aligned with the United Nations SDG goal to reduce premature mortality from NCDs disease by 25% by 2030.